Differences between human slow N-acetyltransferase 2 alleles in levels of 4-aminobiphenyl-induced DNA adducts and mutations

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 671, Issue 1-2, 2009, Pages 13-19

  Bendaly, Jean ^a   Doll, Mark A ^a   Millner, Lori M ^a   Metry, Kristin J ^a   Smith, Ned B ^a   Pierce Jr , William M ^a   Hein, David W ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

4 Aminobiphenyl; Acetylator genotype; DNA adducts; N Acetyltransferase 2

Indexed keywords

4 BIPHENYLAMINE; ARYLAMINE ACETYLTRANSFERASE; CYTOCHROME P450 1A1; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE;

ACETYLATION; ANIMAL CELL; ARTICLE; CANCER RISK; CARCINOGEN DNA INTERACTION; CATALYSIS; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; EXCISION REPAIR; GENETIC POLYMORPHISM; GENOTYPE; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ALLELES; AMINOBIPHENYL COMPOUNDS; ANIMALS; ARYLAMINE N-ACETYLTRANSFERASE; CHO CELLS; CRICETINAE; CRICETULUS; CYTOCHROME P-450 CYP1A1; DNA ADDUCTS; HUMANS; MUTATION; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION; TRANSFECTION;

CRICETULUS GRISEUS;

EID: 70350344950     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.08.003     Document Type: Article

References (69)

1. Stabbert R., Schafer K.H., Biefel C., and Rustemeier K. Analysis of aromatic amines in cigarette smoke. Rapid Commun. Mass Spectrom. 17 (2003) 2125-2132
2. Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Bouvard V., Benbrahim-Tallaa L., and Cogliano V. Carcinogenicity of some aromatic amines, organic dyes, and related exposures. Lancet Oncol. 9 (2008) 322-323
3. Kim D., and Guengerich F.P. Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 27-49
4. Dorrenhaus, Muller T., and Roos P.H. Increased CYP1A1 expression in human exfoliated urothelial cells of cigarette smokers compared to non-smokers. Arch. Toxicol. 81 (2007) 19-25
5. Tsuneoka Y., Dalton T.P., Miller M.L., Clay C.D., Shertzer H.G., Talaska G., Medvedovic M., and Nebert D.W. 4-aminobiphenyl-induced liver and urinary bladder DNA adduct formation in Cyp1a2(-/-) and Cyp1a2(+/+) mice. J. Natl. Cancer Inst. 95 (2003) 1227-1237
6. Talaska G., Ginsburg D., LaDow K., Puga A., Dalton T., and Warshawsky D. Impact of Cyp1a2 or Ahr gene knockout in mice: implications for biomonitoring studies. Toxicol. Lett. 162 (2006) 246-249
7. Firozi P.F., Bondy M.L., Sahin A.A., Chang P., Lukmanji F., Singletary E.S., Hassan M.M., and Li D. Aromatic DNA adducts and polymorphisms of CYP1A1, NAT2, and GSTM1 in breast cancer. Carcinogenesis 23 (2002) 301-306
8. Talaska G., al-Juburi A.Z., and Kadlubar F.F. Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 5350-5354
9. Ricicki E.M., Soglia J.R., Teitel C., Kane R., Kadlubar F., and Vouros P. Detection and quantification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human pancreas tissue using capillary liquid chromatography-microelectrospray mass spectrometry. Chem. Res. Toxicol. 18 (2005) 692-699
10. Hein D.W., Doll M.A., Fretland A.J., Leff M.A., Webb S.J., Xiao G.H., Devanaboyina U.S., Nangju N.A., and Feng Y. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9 (2000) 29-42
11. Tabor H.K., Risch N.J., and Myers R.M. Candidate-gene approaches for studying complex genetic traits: practical considerations. Nat. Rev. Genet. 3 (2002) 391-397
12. Colhoun H.M., McKeigue P.M., and Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet 361 (2003) 865-872
13. Hein D.W. N-acetyltransferase single nucleotide polymorphisms: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Exp. Opin. Drug Metab. Toxicol. 5 (2009) 353-366
14. Ambrosone C.B., Freudenheim J.L., Graham S., Marshall J.R., Vena J.E., Brasure J.R., Michalek A.M., Laughlin R., Nemoto T., Gillenwater K.A., and Shields P.G. Cigarette smoking, N-acetyltransferase 2 genetic polymorphisms, and breast cancer risk. JAMA 276 (1996) 1494-1501
15. Huang C.S., Chern H.D., Shen C.Y., Hsu S.M., and Chang K.J. Association between N-acetyltransferase 2 (NAT2) genetic polymorphism and development of breast cancer in post-menopausal Chinese women in Taiwan, an area of great increase in breast cancer incidence. Int. J. Cancer. 82 (1999) 175-179
16. Alberg A.J., Daudt A., Huang H.Y., Hoffman S.C., Comstock G.W., Helzlsouer K.J., Strickland P.T., and Bell D.A. N-acetyltransferase 2 (NAT2) genotypes, cigarette smoking, and the risk of breast cancer. Cancer Detect. Prev. 28 (2004) 187-193
17. Sillanpaa P., Hirvonen A., Kataja V., Eskelinen M., Kosma V.M., Uusitupa M., Vainio H., and Mitrunen K. NAT2 slow acetylator genotype as an important modifier of breast cancer risk. Int. J. Cancer 114 (2005) 579-584
18. Ambrosone C.B., Kropp S., Yang J., Yao S., Shields P.G., and Chang-Claude J. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 15-26
19. Hunter D.J., Hankinson S.E., Hough H., Gertig D.M., Garcia-Closas M., Spiegelman D., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., and Kelsey K. A prospective study of NAT2 acetylation genotype, cigarette smoking, and risk of breast cancer. Carcinogenesis 18 (1997) 2127-2132
20. Delfino R.J., Smith C., West J.G., Lin H.J., White E., Liao S.Y., Gim J.S., Ma H.L., Butler J., and Anton-Culver H. Breast cancer, passive and active cigarette smoking and N-acetyltransferase 2 genotype. Pharmacogenetics 10 (2000) 461-469
21. Krajinovic M., Ghadirian P., Richer C., Sinnett H., Gandini S., Perret C., Lacroix A., Labuda D., and Sinnett D. Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions. Int. J. Cancer 92 (2001) 220-225
22. Egan K.M., Newcomb P.A., Titus-Ernstoff L., Trentham-Dietz A., Mignone L.I., Farin F., and Hunter D.J. Association of NAT2 and smoking in relation to breast cancer incidence in a population-based case-control study (United States). Cancer Causes Control 14 (2003) 43-51
23. Lash T.L., Bradbury B.D., Wilk J.B., and Aschengrau A. A case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology. Breast Cancer Res. 7 (2005) R385-R393
24. Lissowska J., Brinton L.A., Zatonski W., Blair A., Bardin-Mikolajczak A., Peplonska B., Sherman M.E., Szeszenia-Dabrowska N., Chanock S., and Garcia-Closas M. Tobacco smoking, NAT2 acetylation genotype and breast cancer risk. Int. J. Cancer 119 (2006) 1961-1969
25. Ochs-Balcom H.M., Wiesner G., and Elston R.C. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am. J. Epidemiol. 166 (2007) 246-254
26. Millikan R.C., Pittman G.S., Newman B., Tse C.K., Selmin O., Rockhill B., Savitz D., Moorman P.G., and Bell D.A. Cigarette smoking, N-acetyltransferases 1 and 2, and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 371-378
27. Morabia A., Bernstein M.S., Bouchardy I., Kurtz J., and Morris M.A. Breast cancer and active and passive smoking: the role of the N-acetyltransferase 2 genotype. Am. J. Epidemiol. 152 (2000) 226-232
28. Chang-Claude J., Kropp S., Jager B., Bartsch H., and Risch A. Differential effect of NAT2 on the association between active and passive smoke exposure and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 698-704
29. Thompson L.H., Rubin J.S., Cleaver J.E., Whitmore G.F., and Brookman K. A screening method for isolating DNA repair-deficient mutants of CHO cells. Somat. Cell Genet. 6 (1980) 391-405
30. Weber C.A., Salazar E.P., Stewart S.A., and Thompson L.H. Molecular cloning and biological characterization of a human gene, ERCC2, that corrects the nucleotide excision repair defect in CHO UV5 cells. Mol. Cell. Biol. 8 (1988) 1137-1146
31. Bendaly J., Zhao S., Neale J.R., Metry K.J., Doll M.A., States J.C., Pierce Jr. W.M., and Hein D.W. 2-Amino-3,8-dimethylimidazo-[4,5-f]quinoxaline-induced DNA adduct formation and mutagenesis in DNA repair-deficient Chinese hamster ovary cells expressing human cytochrome P4501A1 and rapid or slow acetylator N-acetyltransferase 2. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1503-1509
32. Metry K.J., Zhao S., Neale J.R., Doll M.A., States J.C., McGregor W.G., Pierce Jr. W.M., and Hein D.W. 2-Amino-1-methyl-6-phenylimidazo [4,5-b] pyridine-induced DNA adducts and genotoxicity in Chinese hamster ovary (CHO) cells expressing human CYP1A2 and rapid or slow acetylator N-acetyltransferase 2. Mol. Carcinog. 46 (2007) 553-563
33. Leff M.A., Fretland A.J., Doll M.A., and Hein D.W. Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype. J. Biol. Chem. 274 (1999) 34519-34522
34. Fretland A.J., Doll M.A., Zhu Y., Smith L., Leff M.A., and Hein D.W. Effect of nucleotide substitutions in N-acetyltransferase-1 on N-acetylation (deactivation) and O-acetylation (activation) of arylamine carcinogens: implications for cancer predisposition. Cancer Detect. Prev. 26 (2002) 10-14
35. Neale J.R., Smith N.B., Pierce W.M., and Hein D.W. Methods for aromatic and heterocyclic amine carcinogen-DNA adduct analysis by liquid chromatography-tandem mass spectrometry. Polycycl. Aromat. Compd. 28 (2008) 402-417
36. Bartsch H., Malaveille C., Friesen M., Kadlubar F.F., and Vineis P. Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV. Molecular dosimetry studies implicate aromatic amines as bladder carcinogens. Eur. J. Cancer 29A (1993) 1199-1207
37. Zayas B., Stillwell S.W., Wishnok J.S., Trudel L.J., Skipper P., Yu M.C., Tannenbaum S.R., and Wogan G.N. Detection and quantification of 4-ABP adducts in DNA from bladder cancer patients. Carcinogenesis 28 (2007) 342-349
38. Gorlewska-Roberts K., Green B., Fares M., Ambrosone C.B., and Kadlubar F.F. Carcinogen-DNA adducts in human breast epithelial cells. Environ. Mol. Mutagen 39 (2002) 184-192
39. Faraglia B., Chen S.Y., Gammon M.D., Zhang Y., Teitelbaum S.L., Neugut A.I., Ahsan H., Garbowski G.C., Hibshoosh H., Lin D., Kadlubar F.F., and Santella R.M. Evaluation of 4-aminobiphenyl-DNA adducts in human breast cancer: the influence of tobacco smoke. Carcinogenesis 24 (2003) 719-725
40. Ambrosone C.B., Abrams S.M., Gorlewska-Roberts K., and Kadlubar F.F. Hair dye use, meat intake, and tobacco exposure and presence of carcinogen-DNA adducts in exfoliated breast ductal epithelial cells. Arch. Biochem. Biophys. 464 (2007) 169-175
41. 32P-postlabeling, and GC/MS detection of 4-aminobiphenyl-DNA adducts in human peripheral lung in relation to metabolic activation pathways involving pulmonary N-oxidation, conjugation, and peroxidation. Mutat. Res. 378 (1997) 97-112
42. Bendaly J., Metry K.J., Doll M.A., Jiang G., States J.C., Smith N.B., Neale J.R., Holloman J.L., Pierce Jr. W.M., and Hein D.W. Role of human CYP1A1 and NAT2 in 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mutagenicity and DNA adducts. Xenobiotica 39 (2009) 399-406
43. Turesky R.J., Bendaly J., Yasa I., Doll M.A., and Hein D.W. The impact of NAT2 acetylator genotype on mutagenesis and DNA adducts from 2-amino-9H-pyrido[2,3-b]indole. Chem. Res. Toxicol. 22 (2009) 726-733
44. Minchin R.F., Reeves P.T., Teitel C.H., McManus M.E., Mojarrabi B., Ilett K.F., and Kadlubar F.F. N-and O-acetylation of aromatic and heterocyclic amine carcinogens by human monomorphic and polymorphic acetyltransferases expressed in COS-1 cells. Biochem. Biophys. Res. Commun. 185 (1992) 839-844
45. Hein D.W., Rustan T.D., Ferguson R.J., Doll M.A., and Gray K. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch. Toxicol. 68 (1994) 129-133
46. Lau E.Y., Felton J.S., and Lightstone F.C. Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study. Chem. Res. Toxicol. 19 (2006) 1182-1190
47. Hein D.W., Doll M.A., Rustan T.D., Gray K., Feng Y., Ferguson R.J., and Grant D.M. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 14 (1993) 1633-1638
48. Zang Y., Doll M.A., Zhao S., States J.C., and Hein D.W. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis 28 (2007) 1665-1671
49. McQueen C.A., Maslansky C.J., Glowinski I.B., Crescenzi S.B., Weber W.W., and Williams G.M. Relationship between the genetically determined acetylator phenotype and DNA damage induced by hydralazine and 2-aminofluorene in cultured rabbit hepatocytes. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 1269-1272
50. Feng Y., Jiang W., and Hein D.W. 2-Aminofluorene-DNA adduct levels in tumor-target and nontarget organs of rapid and slow acetylator Syrian hamsters congenic at the NAT2 locus. Toxicol. Appl. Pharmacol. 141 (1996) 248-255
51. Vermeulen R., Talaska G., Schumann B., Bos R.P., Rothman N., and Kromhout H. Urothelial cell DNA adducts in rubber workers. Environ. Mol. Mutagen 39 (2002) 306-313
52. Agudo A., Peluso M., Sala N., Capella G., Munnia A., Piro S., Marin F., Ibanez R., Amiano P., Tormo M.J., Ardanaz E., Barricarte A., Chirlaque M.D., Dorronsoro M., Larranaga N., Martinez C., Navarro C., Quiros J.R., Sanchez M.J., and Gonzalez C.A. Aromatic DNA adducts and polymorphisms in metabolic genes in healthy adults: findings from the EPIC-Spain cohort. Carcinogenesis 30 (2009) 968-976
53. Zang Y., Doll M.A., States J.C., and Hein D.W. The effect of the G857A(K268R) polymorphism on N-acetyltransferase 2-mediated carcinogen metabolism is substrate-dependent. Proc. Am. Assoc. Cancer Res. 47 (2006) 2033 (abstract)
54. Hein D.W., Ferguson R.J., Doll M.A., Rustan T.D., and Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum. Mol. Genet. 3 (1994) 729-734
55. Hein D.W., Doll M.A., Rustan T.D., and Ferguson R.J. Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res. 55 (1995) 3531-3536
56. Walraven J.M., Zang Y., Trent J.O., and Hein D.W. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr. Drug Metab. 9 (2008) 471-486
57. Zang Y., Zhao S., Doll M.A., States J.C., and Hein D.W. The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation. Pharmacogenetics 14 (2004) 717-723
58. Hein D.W. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 25 (2006) 1649-1658
59. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Lai S.L., Yang S.Y., Chang F.Y., and Lee S.D. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35 (2002) 883-889
60. Makarova S.I. Human N-acetyltransferases and drug-induced hepatotoxicity. Curr. Drug Metab. 9 (2008) 538-545
61. Cho H.J., Koh W.J., Ryu Y.J., Ki C.S., Nam M.H., Kim J.W., and Lee S.Y. Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb.) 87 (2007) 551-556
62. Cartwright R.A., Glashan R.W., Rogers H.J., Ahmad R.A., Barham-Hall D., Higgins E., and Kahn M.A. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2 (1982) 842-845
63. Hein D.W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507 (2002) 65-77
64. Brockmoller J., Cascorbi I., Kerb R., and Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res. 56 (1996) 3915-3925
65. Okkels H., Sigsgaard T., Wolf H., and Autrup H. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 225-231
66. Filiadis I.F., Georgiou I., Alamanos Y., Kranas V., Giannakopoulos X., and Lolis D. Genotypes of N-acetyltransferase-2 and risk of bladder cancer: a case-control study. J. Urol. 161 (1999) 1672-1675
67. El Desoky E.S., AbdelSalam Y.M., Salama R.H., El Akkad M.A., Atanasova S., von Ahsen N., Armstrong V.W., and Oellerich M. NAT2*5/*5 genotype (341T>C) is a potential risk factor for schistosomiasis-associated bladder cancer in Egyptians. Ther. Drug Monit. 27 (2005) 297-304
68. van der Hel O.L., Peeters P.H.M., Hein D.W., Doll M.A., Grobbee D.E., Kromhout D., and de Mesquita H.B.B. NAT2 slow acetylation and GSTM1 null genotypes may increase postmenopausal breast cancer risk in long-term smoking women. Pharmacogenetics 13 (2003) 399-407
69. K.B. Baumgartner, T.J. Schlierf, D. Yang, M.A. Doll and D.W. Hein, N-acetyltransferase 2 genotype modification of active cigarette smoking on breast cancer risk among Hispanic and non-Hispanic white women, Toxicol Sci (2009), doi:10.1093/toxsci/kfp199 (Epub August 19, 2009).